A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
A recent study found a link between HbA1C levels, diabetes status, and long-term cognitive decline.
Brian Bastean, PharmD, MBA, has identified some of the most important and influential research in recent months contributing to value-based care, health economics and outcomes research, and clinical pathways.
The rate of mammogram use increased by nearly 6% among older patients who were recommended for screening after the Affordable Care Act eliminated co-payments.
According to a large prospective real-world study, continuous glucose monitoring provides numerous clinical benefits such as improved glycemic control and quality of life.
When assessing the quality of inpatient heart failure care, hospital adherence to clinical guidelines may be a more important factor than the volume of patients treated.
Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist.
According to a recent research letter, the risk for breast cancer morbidity differs by subtype in survivors of Hodgkin lymphoma treated with radiotherapy.
The US Food and Drug Administration has approved the first radioactive drug for the treatment of a type of pancreatic neuroendocrine cancer.